Bergabunglah dengan Buletin Kami
Bergabunglah dengan daftar pelanggan kami untuk mendapatkan artikel terkini, update dan penawaran khusus langsung di kotak masuk Anda
As one notable company exits the field, growing CDMOs open facilities and secure...
A majority of biopharmas are expected to increase their reliance on CDMOs in com...
As wet-lab validation becomes increasingly important to support artificial intel...
Shinshu University Hospital's expertise in CAR T-cell therapy R&D and clinical a...
Advances in media optimization, cell engineering, and AI are reshaping intensifi...
The entrance of major AI companies into healthcare is a meaningful and welcome d...
AstraZeneca researchers show that automated microscale chromatography can genera...
The operational challenges of making patient-specific cell therapies require car...
Overexpressing the gene Pabpc1 in CHO cell cultures increases productivity by 30...
Scientists developed monoclonal antibodies targeting matrix metalloproteinase-9,...
Intravenous gene therapy extended lifespan, reduced neurological symptoms, and i...
Novel approaches are urgently needed to improve availability of diagnostic assay...
Del-desiran failed the Phase III HARBOR trial (NCT06411288) by missing the study...
Mutant NRAS has remained difficult to target in cancer. New findings suggest tha...
The HiBiT Target Cell Killing (TCK) platform, with off-the-shelf, mix-and-match ...
A more coherent approach: a peptide-mapping LC-HRMS (liquid chromatography-high ...